Non-alcoholic Fatty Liver Disease Clinical Trial
Official title:
Investigation of Pharmacokinetic Properties of Single Subcutaneous Doses of NNC0194-0499 in Chinese Males
Verified date | June 2024 |
Source | Novo Nordisk A/S |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study looks at how a new study medicine called NNC0194-0499 behaves in the body of Chinese men. Three different dose levels will be tested. Participant will get only one of the three different dose levels of NNC0194-0499. Which dose participant will get will be decided by chance. NNC0194-0499 is a medicine under clinical investigation. It means that the medicine has not yet been approved by the health authorities. Participant will get 1 or 2 injections of the study medicine. It will be injected with a needle into a skin fold on stomach. The study will last for a maximum of 64 days. Participant will not be able to take part in the study if the study doctor considers there is a risk for participant's health.
Status | Completed |
Enrollment | 24 |
Est. completion date | June 13, 2023 |
Est. primary completion date | June 13, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 20 Years to 55 Years |
Eligibility | Inclusion Criteria: - Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. - Chinese male aged 20-55 years (both inclusive) at the time of signing informed consent. - Body mass index (BMI) between 23.0 and 34.9 kilograms per meter square (kg/m^2) (both inclusive). - Body weight greater than or equal to 60 kg. - Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator. Exclusion Criteria: - Known or suspected hypersensitivity to study intervention or related products. - Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol. |
Country | Name | City | State |
---|---|---|---|
China | Jinan Central Hospital | Jinan | Shandong |
Lead Sponsor | Collaborator |
---|---|
Novo Nordisk A/S |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | AUC0-8, NNC0194-0499: The area under the NNC0194-0499 serum concentration-time curve from time 0 to infinity after a single dose | Measured in nanomoles*hours per liter (nmol h/L). | From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36) | |
Secondary | AUC0-168h, NNC0194-0499: The area under the NNC0194-0499 serum concentration-time curve from time 0 to 168 hours after a single dose | Measured in nmol h/L. | From Day 1 (pre-dose) until Day 7 (168 hours) | |
Secondary | Cmax, NNC0194-0499: The maximum concentration of NNC0194- 0499 in serum | Measured in nmol/L. | From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36) | |
Secondary | tmax, NNC0194-0499: The time from dose administration to maximum serum concentration of NNC0194-0499 | Measured in hours. | From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36) | |
Secondary | t1/2, NNC0194-0499: The terminal half-life of NNC0194-0499 | Measured in hours. | From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36) | |
Secondary | CL/FNNC0194-0499: The apparent total serum clearance of NNC0194-0499 | Measured in liters per hour (L/h). | From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36) | |
Secondary | Vz/FNNC0194-0499: The apparent volume of distribution of NNC0194-0499 in the terminal phase | Measured in liters (L). | From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36) | |
Secondary | Relative change in triglycerides | Measured in Percent change. | From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36) | |
Secondary | Relative change in high-density lipoprotein (HDL) cholesterol | Measured in Percent change. | From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36) | |
Secondary | Relative change in low-density lipoprotein (LDL) cholesterol | Measured in Percent change. | From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05480696 -
Soluble Fibre Supplementation in NAFLD
|
Phase 1 | |
Active, not recruiting |
NCT02500147 -
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
|
Phase 4 | |
Completed |
NCT04671186 -
Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan
|
N/A | |
Recruiting |
NCT05979779 -
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
|
Phase 2 | |
Recruiting |
NCT05462353 -
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH
|
Phase 2 | |
Completed |
NCT05006885 -
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
|
Phase 1 | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Recruiting |
NCT04365855 -
The Olmsted NAFLD Epidemiology Study (TONES)
|
N/A | |
Recruiting |
NCT05618626 -
Prevention of NAFLD and CVD Through Lifestyle Intervention
|
N/A | |
Completed |
NCT03256526 -
6-week Safety and PD Study in Adults With NAFLD
|
Phase 2 | |
Enrolling by invitation |
NCT06152991 -
Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy
|
Phase 3 | |
Completed |
NCT03681457 -
Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects
|
Phase 1 | |
Completed |
NCT06244550 -
Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors
|
N/A | |
Not yet recruiting |
NCT05120557 -
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
|
N/A | |
Completed |
NCT03060694 -
Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements
|
||
Completed |
NCT02526732 -
Hepatic Inflammation and Physical Performance in Patients With NASH
|
N/A | |
Recruiting |
NCT01988441 -
The Influence of Autophagy on Fatty Liver
|
||
Recruiting |
NCT01680003 -
Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
Completed |
NCT01712711 -
Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
Recruiting |
NCT00941642 -
Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease
|
Phase 4 |